Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TAK 
Takeda Pharmaceutical Co Ltd ADR (TAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.7
1 Year Target Price $17.7
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.12% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 47.55B USD | Price to earnings Ratio 51.69 | 1Y Target Price 17.7 |
Price to earnings Ratio 51.69 | 1Y Target Price 17.7 | ||
Volume (30-day avg) 4 | Beta 0.27 | 52 Weeks Range 12.51 - 15.56 | Updated Date 08/29/2025 |
52 Weeks Range 12.51 - 15.56 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 4.44% | Basic EPS (TTM) 0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.06% | Operating Margin (TTM) 16.89% |
Management Effectiveness
Return on Assets (TTM) 2.31% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 51.69 | Forward PE 14.73 | Enterprise Value 75122931922 | Price to Sales(TTM) 0.01 |
Enterprise Value 75122931922 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 9.84 | Shares Outstanding 3158220032 | Shares Floating 1561025417 |
Shares Outstanding 3158220032 | Shares Floating 1561025417 | ||
Percent Insiders 0.01 | Percent Institutions 2.5 |
Upturn AI SWOT
Takeda Pharmaceutical Co Ltd ADR
Company Overview
History and Background
Takeda Pharmaceutical was founded in 1781 in Osaka, Japan. Initially a traditional medicine vendor, it evolved into a research-based pharmaceutical company. Significant milestones include international expansion, strategic acquisitions (e.g., Shire), and a focus on innovative therapies.
Core Business Areas
- Gastroenterology: Focuses on treatments for gastrointestinal disorders like inflammatory bowel disease (IBD).
- Rare Diseases: Develops therapies for rare genetic and hematologic conditions.
- Plasma-Derived Therapies: Produces plasma-based products for immune deficiencies and other disorders.
- Oncology: Develops treatments for various cancers, including hematologic malignancies and solid tumors.
- Neuroscience: Offers therapies for neurological and psychiatric disorders such as ADHD and depression.
Leadership and Structure
Takeda is led by its President and CEO, Christophe Weber. The company operates with a global structure, organized by therapeutic areas and geographic regions.
Top Products and Market Share
Key Offerings
- Entyvio: An anti-inflammatory drug used to treat ulcerative colitis and Crohn's disease. Competitors include Humira (ABBV), Remicade, and Stelara (JNJ). Generated approximately $4.8 billion in revenue in FY2023. Market share is significant in the IBD market but varies by region and indication.
- Vyvanse/Elvanse: A stimulant medication used to treat ADHD and binge-eating disorder. Revenue approximately $2.5 billion in FY2023. Competitors are Adderall, Concerta and Ritalin. Market share is substantial but facing generic competition.
- Immunoglobulin Therapies (e.g., Gammagard Liquid and Cuvitru): Plasma-derived therapies used to treat immunodeficiency and autoimmune disorders. Annual revenue generation is approximately $2.3 billion. Main competitors include Grifols and CSL.
- Livtencity: For post-transplant cytomegalovirus (CMV) infection. This is a newer drug with growing revenue and market share. Competitors include Letermovir (Prevymis) from Merck.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory oversight, and increasing competition from generic drugs. The industry is also seeing growth in biologics and personalized medicine.
Positioning
Takeda is a global pharmaceutical company with a strong presence in gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its competitive advantages include a diverse product portfolio, global reach, and strong R&D pipeline.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1.4 trillion USD. Takeda's positioning in key therapeutic areas allows it to address a significant portion of this TAM, focusing on specialty markets with high unmet needs.
Upturn SWOT Analysis
Strengths
- Global presence
- Diverse product portfolio
- Strong R&D pipeline
- Expertise in rare diseases
- Established plasma-derived therapies business
Weaknesses
- High debt levels following the Shire acquisition
- Exposure to generic competition
- Dependence on key products
- Integration challenges related to acquisitions
- Currency fluctuation risks
Opportunities
- Growth in emerging markets
- Development of innovative therapies
- Expansion of existing product lines
- Strategic partnerships and collaborations
- Increasing demand for rare disease treatments
Threats
- Patent expirations
- Pricing pressures
- Regulatory changes
- Competition from other pharmaceutical companies
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- ABBV
Competitive Landscape
Takeda competes with major pharmaceutical companies on a global scale. Its strengths lie in its specialized therapies and global reach, but it faces challenges related to debt, competition, and regulatory pressures.
Major Acquisitions
Shire
- Year: 2019
- Acquisition Price (USD millions): 62000
- Strategic Rationale: Acquired Shire to expand its portfolio in rare diseases and specialty areas, significantly increasing its global scale and innovation capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and product development.
Future Projections: Analysts project moderate revenue growth, driven by new product launches and expansion in emerging markets.
Recent Initiatives: Recent initiatives include focusing on core business areas, divesting non-core assets, and investing in R&D.
Summary
Takeda is a large global pharmaceutical company with a diverse portfolio and strong presence in specialty therapeutic areas. The Shire acquisition significantly increased its scale but also created high debt levels, which the company is actively addressing. Key strengths include innovative therapies and a global reach, while challenges include debt reduction, patent expirations, and competition. Overall it is a weak company with a lot of debt. It needs to improve its EPS and dividend payout.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K reports)
- Analyst reports from major investment banks
- Industry publications (e.g., FiercePharma, EvaluatePharma)
- Company Investor Relations website
- Yahoo Finance
- Bloomberg
- MarketWatch
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data may be estimates and subject to change. AI rating is based on available information and algorithmic interpretation, and should be regarded as only one factor in any investment evaluation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Takeda Pharmaceutical Co Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2008-10-27 | President, CEO & Representative Director Mr. Christophe Weber | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 47455 | Website https://www.takeda.com |
Full time employees 47455 | Website https://www.takeda.com | ||
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.